Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
Ann Oncol. 2021 Jul;32(7):936-937.
doi: 10.1016/j.annonc.2021.04.006.
Epub 2021 Apr 15.
1 Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
2 Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
3 Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
4 Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France.
5 Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France.
6 Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpital de Paris, Hôpital Universitaire Bicêtre, Le Kremlin Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France; CEA, DSV/iMETI, IDMIT, Fontenay-aux-Roses, France.
7 Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: [email protected].